Enanta Pharmaceuticals Inc. (ENTA) Receives $25.36 Average Price Target from Brokerages
Shares of Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) have received an average rating of “Hold” from the seven analysts that are covering the firm. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and two have given a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $25.36.
ENTA has been the topic of several research analyst reports. JPMorgan Chase & Co. set a $26.00 price target on shares of Enanta Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 9th. Zacks Investment Research raised shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $30.00 price target on the stock in a report on Tuesday, September 27th.
Enanta Pharmaceuticals (NASDAQ:ENTA) opened at 28.14 on Wednesday. The stock has a 50 day moving average of $25.01 and a 200-day moving average of $23.98. Enanta Pharmaceuticals has a 1-year low of $20.39 and a 1-year high of $34.49. The company has a market cap of $535.64 million, a PE ratio of 18.61 and a beta of 0.61.
Several hedge funds and other institutional investors have recently made changes to their positions in ENTA. BlackRock Fund Advisors raised its position in shares of Enanta Pharmaceuticals by 7.6% in the third quarter. BlackRock Fund Advisors now owns 1,293,604 shares of the company’s stock worth $34,423,000 after buying an additional 91,672 shares during the last quarter. Eagle Asset Management Inc. raised its stake in Enanta Pharmaceuticals by 0.8% in the second quarter. Eagle Asset Management Inc. now owns 1,001,572 shares of the company’s stock valued at $22,084,000 after buying an additional 7,747 shares in the last quarter. FMR LLC raised its stake in Enanta Pharmaceuticals by 7.9% in the second quarter. FMR LLC now owns 700,653 shares of the company’s stock valued at $15,449,000 after buying an additional 51,538 shares in the last quarter. State Street Corp raised its stake in Enanta Pharmaceuticals by 12.2% in the second quarter. State Street Corp now owns 652,261 shares of the company’s stock valued at $14,382,000 after buying an additional 70,709 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in Enanta Pharmaceuticals by 3.0% in the second quarter. Vanguard Group Inc. now owns 650,560 shares of the company’s stock valued at $14,345,000 after buying an additional 19,071 shares in the last quarter. Hedge funds and other institutional investors own 65.68% of the company’s stock.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC).
Receive News & Stock Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.